Search: onr:"swepub:oai:gup.ub.gu.se/193544" >
Health economic cos...
-
Jansson, Sven-ArneUmeå universitet,Yrkes- och miljömedicin
(author)
Health economic costs of COPD in Sweden by disease severity - Has it changed during a ten years period?
- Article/chapterEnglish2013
Publisher, publication year, extent ...
Numbers
-
LIBRIS-ID:oai:gup.ub.gu.se/193544
-
https://gup.ub.gu.se/publication/193544URI
-
https://doi.org/10.1016/j.rmed.2013.07.012DOI
-
https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-84946URI
Supplementary language notes
Part of subdatabase
Classification
-
Subject category:ref swepub-contenttype
-
Subject category:art swepub-publicationtype
Notes
-
Objectives: The objectives of the presented study were to estimate societal costs of COPD in Sweden, the relationship between costs and disease severity, and possible changes in the costs during the last decade. Methods: Subjects with COPD derived from the general population in Northern Sweden were interviewed by telephone regarding their resource utilisation and productivity losses four times quarterly during 2009-10. Mean annual costs were estimated for each severity stage of COPD. Results: A strong relationship was found between disease severity and costs. Estimated mean annual costs per subject of mild, moderate, severe and very severe COPD amounted to 596 (SEK 5686), 3245 (SEK 30,957), 5686 (SEK 54,242), and 17,355 euros (SEK 165,569), respectively. The main cost drivers for direct costs were hospitalisations (for very severe COPD) and drugs (all other severity stages). The main cost driver for indirect costs was productivity loss due to sick-leave (for mild COPD) and early retirement (all other severity stages). Costs appeared to be lower in 2010 than in 1999 for subjects with severe and very severe COPD, but higher for those with mild and moderate COPD. Conclusion: Our results show that costs of COPD are strongly related to disease severity, and scaling the data to the whole Swedish population indicates that the total costs in Sweden amounted to 1.5 billion euros (SEK 13.9 bn) in 2010. In addition, costs have decreased since 1999 for subjects with severe and very severe COPD, but increased for those with mild and moderate COPD. (C) 2013 Elsevier Ltd. All rights reserved.
Subject headings and genre
Added entries (persons, corporate bodies, meetings, titles ...)
-
Backman, HelenaUmeå universitet,Yrkes- och miljömedicin(Swepub:umu)heaban01
(author)
-
Stenling, AnnaAstraZeneca Nordic-Baltic, Department of Health Economics, SE-151 85 Södertälje, Sweden(Swepub:umu)anabei01
(author)
-
Lindberg, AnneUmeå universitet,Medicin(Swepub:umu)anelig02
(author)
-
Rönmark, EvaUmeå universitet,Yrkes- och miljömedicin(Swepub:umu)evra0004
(author)
-
Lundbäck, Bo,1948Gothenburg University,Göteborgs universitet,Krefting Research Centre(Swepub:gu)xlunbo
(author)
-
Umeå universitetYrkes- och miljömedicin
(creator_code:org_t)
Related titles
-
In:Respiratory Medicine: Elsevier BV107:12, s. 1931-19380954-61111532-3064
Internet link
Find in a library
To the university's database